Table 5.
Study Group | Number. of patients |
|||
---|---|---|---|---|
0 month | 3 months | 6 months | 12 months | |
Timolol group (n=21) | 3 | 6 | 8 | 12 (57%) |
Pilocarpine group (n=22) | 2 | 4 | 6 | 9 (41%) |
Brimonidine group (n=22) | 3 | 3 | 5 | 8 (36%) |
Latanoprost group (n=23) | 1 | 5 | 8 | 11 (48%) |